Introduction
A number of studies have investigated the methylation status of the human papillomavirus genome both in the context of the viral life cycle and associated neoplastic disease (summarized in Table 1 ). Most of these studies have focused on the high risk HPV most commonly associated with human cancer, HPV16, with a few studies looking at other high risk HPVs. Until recently, studies have focused on evaluating the methylation status of the HPV long control region (LCR; also referred to as the upstream regulatory region or URR) which contains the viral promoter driving expression of early genes including the viral oncogenes E6 and E7 that are frequently found expressed in HPV-associated neoplastic disease including cancers, the viral transcriptional enhancer, and the viral origin of DNA replication. Also commonly analyzed are regions neighboring the LCR on the circular double stranded DNA genome, including the 3′ region of L1, which is upstream of the LCR, and the E6 gene, which is downstream of the LCR. Studies have employed the use of methylation-sensitive restriction endonucleases and/or bisulfite treatment to distinguish methylated from unmethylated cytosines. In the latter case, the standard approach has been to PCR amplify bisulfite-treated DNA using regional specific primers followed by sequencing of the amplimer products directly or after cloning (the latter having the advantage that one identifies the methylation status of individual copies of the viral genome as opposed to the average methylation state of multiple genomes). More recently deep sequencing technologies have been used to interrogate the methylation status of bisulfite treated DNA, allowing one to look at the whole viral genome, as opposed to specific PCRamplified regions. Table 1 lists these studies and provides a synopsis of the methods used to analyze the methylation patterns, the regions of the viral genome analyzed, and the major findings. In addition to studies evaluating the methylation status of the viral genome, recent chromatin-immunoprecipitation/sequencing (ChIPseq) analyses performed on HeLa cells, which were derived from an HPV18-positive cervical cancer, have provided important new insights into the epigenetic state and transcription factor occupancy of human chromosomes. We now report the reanalysis of these datasets to determine the histone modification status as well as the occupancy of host transcriptional machinery on the HPV18 genome in these cancer cells.
The general conclusion that can be drawn from the studies listed in Table 1 
genome is dynamic both in the context of the viral life cycle and associated neoplastic disease. The latter point has led to the suggestion that the methylation status of the HPV genome may be diagnostic if not prognostic of neoplastic progression as detailed below. That the methylation status is dynamic both in the context of the viral life cycle and associated neoplastic progression supports the hypothesis that epigenetic regulation of viral gene expression is an important factor in HPV-associated disease. Another observation is that the viral genome likely is subjected to de novo methylation by host DNA methyltransferases (DNMTs) implicated in innate responses to pathogens. Thus methylation of the viral genome may be in part a mechanism by which the host attempts to suppress viral gene expression and thereby HPV pathogenicity. In the context of HeLa cells, we find that there is also found localized distinctions in the histone modification status of the chromatin assembled on the HPV18 genome that correlates with the occupancy of host transcriptional machinery specifically within the LCR. Intriguingly, the viral oncogenes modulate the epigenetic machinery of the host through their interplay with both DNMT (Au Yeung et al., 2010; Hsu et al., 2012; Laurson et al., 2010) as well as histone modification enzymes (Bodily et al., 2011; Hyland et al., 2011; McLaughlin-Drubin et al., 2011) . This interplay has implications not only on the epigenetic regulation of the viral genome but also the host genome, and may play an essential role both in the viral life cycle and also associated neoplastic disease.
As part of the series of articles in this special issue of Virology that are tied to the PAVE database, this article focuses on summarizing the knowledge gained from methylation and ChIP-seq analyses of HPV genomes. In the latter regard, we report the results of our re-analysis of ChIP-seq data from studies performed on HeLa cells to determine the occupancy of modified histones and transcription factors on the HPV18 genome. Implications of this analysis of ChIP-seq data on the epigenetic control of viral gene expression are discussed. The reader is also directed to other recent reviews focusing on the potential value of methylation analyses of the HPV genome in diagnosing/predicting HPV-associated disease , and the epigenetics of the host chromosome in the context of HPV-associated disease (Szalmas and Konya, 2009 ). This article is divided into four parts: (1) the methylation status of the viral genome in the context of the viral life cycle, (2) the methylation status of the viral genome in neoplastic progression, (3) the influence of methylation status on the function of the viral E2 transcription factor, and (4) the analysis of ChIP-seq data from studies performed on HeLa cells with regard to the HPV18 genome. This study analyzed the methylation status of the LCR in a clonal cell line, W12E, derived from an HPV16-positive CIN , that harbors the viral genome as an extrachromosomal nuclear plasmid and that upon induction of differentiation supports the productive stage of the viral life cycle as evidenced by the production of virus particles (Flores and Lambert, 1997) . Their analyses demonstrated that de novo host DNA methyltransferases must be acting to modify the viral genome given the pattern of cytosine methylation at not only CpG dinucleotides but other CpX dinucleotides. They also learned, that upon induction of differentiation, the viral LCR becomes hypomethylated, demonstrating that the methylation status of the viral genome is dynamic. A more recent study by Vinokurova and von Knebel Doeberitz (2011) analyzed the methylation status of the HPV16 LCR in distinct stages of the viral life cycle in patient derived tissues, using laser microdissection to capture different layers of the epithelium within the infectious lesions. They also found dynamic changes in the methylation status of the HPV16 LCR in the context of the viral life cycle; however with some differences in the nature of those changes. Specifically, within the terminally differentiated epithelial compartment that was supporting the late stages of the viral life cycle as evidenced by capsid protein expression, they saw a decrease in methylation in the transcriptional enhancer region within the LCR, similar to what was observed in the earlier study. But they also observed an increase in methylation within the region of the LCR containing the early promoter. Interestingly among the sites hypermethylated in the promoter region were sites within the viral E2 transcription factor binding sites that are thought to mediate transcriptional repression of the early promoter. The implications of this observation are discussed in part 3.
Methylation status of the viral genome in neoplastic progression
HPV-associated neoplasia is a progressive disease that has been well defined in the case of cervical carcinogenesis. High risk HPV infections progress through different stages of precancerous disease states, referred to as cervical intraepithelial neoplasia (CIN) grades 1-3 associated with decreasing degrees of epithelial differentiation and increasing degrees of dysplasia including the accumulation of cells with enlarged nuclei. From CIN3 can arise carcinomas or adenocarcinomas. The Pap smear is a commonly utilized cytological assay designed to identify CINs before they can progress to cancers, providing an effective means of intervention in preventing cervical cancer. These common cytological preparations along with biopsies both from CINs that are obtained from patients with positive Pap smears, and cervical cancers have provided a rich source of clinical material that has been exploited to perform epigenetic studies on high risk HPVs in the context of neoplastic progression. Kalantari et al. (2004) , who analyzed the LCR and adjoining regions of the HPV16 genome by sequencing of bisulfite treated DNA first observed that methylation within the 3-region of the L1 gene is associated with neoplastic progression: this region was heavily methylated in cervical cancers but poorly methylated in low grade CINs. These findings were validated by a number of follow-up studies (Balderas-Loaeza et al., 2007; Kalantari et al., 2010 Kalantari et al., , 2009 Kalantari et al., , 2008b including two that evaluated the methylation status of the whole genome (Brandsma et al., 2009; Hernandez et al., 2012) in which hypermethylation of not only the HPV16 L1 gene but also the L2 and E5 genes were observed in more severe neoplastic disease in the cervix. Mirabello et al. (2013) found increased methylation in E2, L2, and L1 genes was associated with increased risk of CIN3 in the context of serial sets of samples taken from women. Thus increases in methylation of the structural genes and E2 may not only be diagnostic of high grade CIN and cancer but also of potential prognostic value in predicting progression.
Changes in methylation within the LCR have also been seen as a function of neoplastic progression; however, the direction of those changes differ between studies. Badal et al. (2004) observed decreased methylation of the LCR in HPV16-positive CINs compared to HPV16-positve samples with normal cytology, an observation that has been reproduced in several other studies (Hublarova et al., 2009; Mazumder Indra et al., 2011; Piyathilake et al., 2011; Xi et al., 2011) that also included the evaluation of cervical cancers. Whereas, others (Bhattacharjee and Sengupta, 2006; Ding et al., 2009; Hong et al., 2008) found increasing methylation within the LCR in more advanced cervical neoplasia. The reason for these disparities is not understood but may reflect differences in the types of techniques used to analyze methylation state of the viral genome and/or differences in the state of the viral genome within lesions as discussed below.
It is potentially important to consider the interplay between the viral genome's state within neoplasias and epigenetic regulation of viral gene expression. During the viral life cycle the viral genome is maintained as a circular, extrachromosomal, nuclear plasmid. Here the viral E1 and E2 proteins play a critical role in the replication and inheritance of the extrachromosomal viral genome in the proliferating compartment of the infected epithelium (McBride et al., 2006) . E1 acts as a DNA helicase to unwind the viral genome at the growing replication fork. E2, in addition to its role as a transcription factor, recruits the E1 protein to the viral genome to allow it to function as a viral genome-specific DNA helicase, and functions to tether the viral genome to host chromosomes during cell division allowing for the efficient inheritance of the viral genome to daughter cells. During neoplastic progression, the high risk HPV genomes often but not always are found to become integrated into the host genome. Integration often arises at fragile sites within the host genome, sites prone to undergoing genetic recombination (Popescu and DiPaolo, 1990; Smith et al., 1992) . These recombination events commonly occur within the 3′ early region of the virus and often result in the deletion of part of the viral genome 3′ to the recombination break point, with continued if not enhanced expression of the two viral oncogenes E6 and E7. Genes disrupted and/or deleted by the integration events include E1, E2, E4, E5 and L2. One of these viral gene products, E2, is known to repress transcription of the viral early genes including the oncogenes E6 and E7 (Thierry and Howley, 1991) . Two types of integration are found in HPV-associated neoplasias . Type 1 integration events are ones in which a single copy of the viral genome becomes integrated in the host chromosome. Type 2 integration events are ones in which a concatomer of viral genomes integrates into a site within the host chromosome. In both cases one can find situations in which the integrated viral genomes and neighboring host DNA are amplified. In the cases of type 2 integration events, it is often found that only the 3′ most copy of the viral genome (the one that is disrupted by the integration event) is transcriptionally active. The other intact copies of the viral genome appear not to give rise to mRNAs that accumulate in the cells. One contributing reason for this difference may be that the mRNAs arising from the junction copy contain 3′UTRs derived from host DNA. These chimeric viral/ host mRNAs were found to be more stable than viral transcripts arising from the intact viral genome at least in part because the viral early mRNA 3′ UTR contains an mRNA instability element . Another possible reason, of relevance to this discussion, is that the internal copies of the viral genome within the concatomer are transcriptionally silenced. If so, then a likely cause would be epigenetic silencing. Unfortunately, sufficient attention has not been given to the genomic state of the HPV genome in most methylation studies, and only one study has distinguished between type 1 vs type 2 integration events. In that study utilizing clonal W12 lines derived from the HPV16-positive CIN (Kalantari et al., 2008a) , differences in methylation status were observed, with type 2 integration events associated with greater hypermethylation of the LCR. This finding is consistent with the hypothesis that internal copies of the viral genome are epigenetically silenced.
Role of DNA methylation in the control of the function of the papillomaviral E2 factor
The viral E2 open reading frame encodes for multiple proteins that regulate the transcription of the viral genome through their ability to bind specific palindromic sites on the viral genome called E2 binding sites (E2BS). E2BS have the consensus sequence 5′-ACCGNNNNCGGT-3′. The Gaston lab demonstrated that methylation of the CpG motifs within E2BS inhibits the binding of E2 protein to its DNA binding site in vitro (Thain et al., 1997) . Kim et al. (2003) subsequently demonstrated that methylation of E2BSs in the context of reporter plasmids inhibited the transcriptional transactivation activity of E2 in transfected cells. As mentioned before, E2 also plays roles both in the initiation of viral DNA replication, by helping to assemble the viral E1 DNA helicase at the origin of viral DNA replication, and in partitioning of the viral DNA to daughter cells during cell division. Both of these activities of E2 also rely upon its ability to bind E2BSs within the LCR, and therefore also are predicted to be modulated by the methylation status of the E2BSs, though this has not been directly demonstrated. Interestingly, in the context of the high risk HPV genomes, the E2 transcriptional transactivator can play two opposing roles, one as an activator of transcription of the viral early promoter, and second as a repressor of transcription from the same promoter. These differences are thought to reflect the occupancy of different E2BSs.
A number of labs have interrogated the methylation status of E2BS in natural HPV infections and in cell lines derived from those infections. Two studies investigated the methylation pattern of the HPV16 genome in clonal cell lines derived from a CIN lesion, the before-mentioned W12E cells and W12I cells in which the viral DNA is found integrated into the host genome as type 1 or type 2 integrants (Kalantari et al., 2008a; Kim et al., 2003) . In W12E cells maintained in the undifferentiated state, E2BSs present on the extrachromosomal viral genomes were frequently found to be methylated. This would suggest that E2 binding is suppressed in these cells. However, when these same cells were induced to undergo terminal differentiation, a condition in which the papillomaviral genome is amplified and progeny virus is made, those same E2BSs became unmethylated. A permutation on this differentiation-dependent changes in methylation status of E2BS was observed in before-mentioned study by Vinokurova and von Knebel Doeberitz (2011) . Here the investigators again saw the differentiation-dependent reduction in methylation of CpGs in the 5′ and central region of the LCR, however, in the 3′ end, containing the 3 E2BSs more proximal to the viral early promoter, the E2BSs became hypermethylated. Such hypermethylation was not apparent in the differentiated W12E cells. The reason for these differences has not been elucidated; however, one would predict that the methylation of the E2BSs in the differentiated cells within naturally arising lesions may release the viral promoter from E2-mediated transcriptional repression.
E2BS were also found to be methylated in cells derived from cervical cancers (Bhattacharjee and Sengupta, 2006) . Methylation of E2BS appears to change during neoplastic progression and depend upon the integration status of the viral genome within cancers (Chaiwongkot et al., 2013) . In cervical lesions, be they precancers or cancers, in which the viral genome exists in the extrachromosomal state, E2BS tend be hypermethylated. In cervical cancers wherein a single copy of the viral genome is integrated into the host genome (and E2 is presumed lost due to integration), the E2BS tend to be hypomethylated. And in cervical cancers in which the viral genome is integrated as a concatomer, most copies have hypermethylated E2BS, while a minority are hypomethylated.
The consequence of hypermethylation of E2BSs on viral transcription and viral DNA replication may differ depending upon the location of the four E2BS that are all located within the LCR. Those more proximal to the viral early promoter and the viral origin of viral DNA replication are thought to mediate E2-dependent transcriptional repression, as well as E1-dependent replication. Consequently, methylation of these promoter proximal sites could activate transcription of the viral early genes while inhibiting E1-dependent replication. Binding by E2 to the promoter distal E2BS, located in the 5′ end of the LCR, has long been thought to mediate E2 dependent transcriptional transactivation of the viral E2 promoter; however a recent study suggests this may not be the case (Vinokurova and von Knebel Doeberitz, 2011) .
Analysis of ChIP-seq data from studies performed on HeLa cells
The recent application of ChIP-seq and RNA-seq methodologies to the study of human cancers provides a new opportunity to identify epigenetic marks on tumor virus genomes, and correlate these marks with viral gene expression in the context of neoplastic diseases caused by these viruses. This is particularly true for HPV18 in the context of cervical cancer, because of the abundance of ChIPseq and RNA-seq data now available for HeLa cells. This rich resource is a direct consequence of the fact that HeLa cells have held historical importance as the standard cell type for the study of mammalian transcriptional machinery and chromatin, and therefore have been used extensively for ChIP-seq studies. We analyzed the published datasets from HeLa-S3 cells with the goal of defining the occupancy of histones and transcription factors on the HPV18 genome found integrated in HeLa cells. Data from 123 ChIP-seq and two RNA-seq experiments were downloaded from the supporting website of the ENCODE project (Rosenbloom et al., 2012) . For each dataset, we mapped all raw short reads to the reference HPV18 genome [X05015.1], using the Maq rapid aligner (Li et al., 2008) . Mapped reads were used to generate continuous tag sequence density tracks with Fseq (Boyle et al., 2008) or python scripts (Heilmann et al., 2012) and displayed on a local installation of the UCSC genome browser (see Table 2 for summary of results). The complete data set for the HPV18 genome, assembled from the 145 ChIP-seq and 2 RNA-seq experiments, is available on PAVE.
Histone modification state of HPV18 chromatin in HeLa cells
Chromatin immunoprecipitation of histone marks associated with active transcription (H3K4me1, H3K4me3, H3K9Ac, H3K27Ac, H3K36me3) were enriched for HPV18 genome sequences (Fig. 1,  right panel) . By contrast, ChIP-seq for facultative (H3K27me3) and constitutive (H3K9me3) heterochromatin marks retrieved only minimal HPV18 sequences. These results suggest that all of the HPV18 genomes integrated in HeLa-S3 cells are transcriptionally active. The H3K4me1 mark was greatest over the long control region (LCR) and diminished after the transcriptional start site (TSS). As seen with cell genes, the H3K4me3 and H3K9Ac marks were enriched at the promoter, but also extended into the first exon. Trimethylation of lysine 36 of histone 3 (H3K36me3), believed to be important for suppression of cryptic TSSs within gene (Joshi and Struhl, 2005) extended throughout the transcribed region. The fact that low signal was observed near the TSS in all of the histone tracks, suggests that the LCR may be histone depleted. Although previous studies have suggested this region is organized into nucleosomes, one possible explanation for apparent discrepancy is that extensive transcription factor binding to the LCR (discussed below) rather than histone binding may account for the observed nuclease protection of this region (Stunkel and Bernard, 1999) . Of note, the abrupt loss of histone marks seen upstream of the LCR (most obvious at the 5′ end of the H3K36me3 track) and downstream within E2 correspond to the deletions within the HPV18 genome that exist within the integrated copies of the HPV18 genome in HeLa cells (Meissner, 1999) . RNA-seq experiments were consistent with transcription initiating at the viral early (P 105 ) promoter and the transcribed region extending from just upstream of the E6 gene through most of the E1 gene (Fig. 1, right panel) . This is in good agreement with the E6-E7-ΔE1 transcript that gives rise to the 3.1 kb mRNA. In both experiments, the mapped reads were greater over the E6 and E7 genes than E1, likely reflecting the presence of the E6 n -E7 transcript as well (Inagaki et al., 1988) . Binding of the basal transcription factors TBP, TAF2F, and TAF1 were highest at the transcriptional start site (TSS) at the P 105 promoter. Although RNA polymerase II signal is typically also highest at the TSS, indicative of pausing during transcript initiation, high pol II signal was observed at the TSS as well as multiple downstream sites. This may indicate rapid assembly of initiation at the LCR or that RNA polymerase II pausing, possibly regulatory in nature, is also occurring downstream of the TSS.
Examination of 4 independent ChIP-seq experiments did not provide any evidence for CTCF binding to the HPV18 genome in HeLa cells (Fig. 2) . The CTCF-associated cohesion complex proteins Rad21 and SMC3 did bind within the LCR and at the 3′ end of the genome near the integration site. These proteins have been implicated in chromosome structure as well as DNA repair. Another DNA repair protein, BRCA1 was observed to bind at the LCR. Future studies will be needed to determine if these binding locations are reflective of the chromatin organization of HPV18 in general or are unique to the integration event in cancer cells in general or HeLa cells in particular.
Transcription factor occupancy on the HPV18 LCR in HeLa cells
Extensive transcription factor binding was observed in the central LCR enhancer (Fig. 3) . This included well-studied factors such as AP1 (Jun/Fos), Stat1, E2F1, and CEBP-beta as well as potentially novel binding factors like Elk1, IRF3, MafK, MAZ, USF2, and ZKSCAN. Several potential heterodimers can be inferred to bind, including c-myc/max, Stat1/Stat3, and c-Fos/JunD. MafK and USF2 are also likely to fall into this category, but their heterodimerizing partners have not been studied. Interestingly, a recent study demonstrated that the LCR was highly responsive to c-myc expression (Sichero et al., 2012 ) consistent with the results Fig. 3 . ChIP-seq experiments using HeLa-S3 cells confirm binding of transcription factors known to bind the HPV18 LCR (left panel) and identify novel binding factors (right panel). All factors were found to bind between the 3 proximal E2 binding sites and the single upstream E2 site (shown in magenta in the annotation track). HPV annotation is shown above the ChIP-seq experiments. For most transcription factors, binding was identified in both replicates; however, for a few transcription factors binding was only observed in one experiment (e.g., NRSF).
reported here (Fig. 3) indicating that the LCR is indeed bound by cmyc in cervical cancer cells. Because of the resolution of the ChIPseq experiments is only about 100 bp, it was only possible to determine whether a transcription factor bound, but not precisely where. Indeed, although there are two AP1 sites within the LCR, both the cFos and JunD ChIP-seq contain only single peak; it is not clear whether this single peak reflects binding to one or both of the closely spaced sites. Of potential interest is that for some transcription factors, a strong signal was observed in one ChIP-seq replicate, but not in the other (see Table 2 ). These included c-myc, E2F4, Elk4, IRF3, Nrf1, NRSF, and Stat1 (for example, see Fig. 3 , compare NSRF replicates 1 and 2). Although this may raise doubts about whether these transcription factors bind to the LCR at all, it also raises the more interesting possibility that binding of some transcription factors is dynamic (e.g., dependent upon activation of stress response pathways or interferon signaling). Further studies will be needed to determine if these dynamic binding events, if real, result in significant changes in the expression levels of HPV oncogenes.
One transcription factor, NRF1, was observed to bind outside of the LCR (Fig. 4) . This was only observed in one replicate and the peak contained a sequencing artifact (column extending from center of the peak) that corresponded to a G/AT repeat motif at the 3′ end of the L1 gene. Whether this binding is real and biologically significant remains to be determined. It is worth noting that this same repeat was found to be expanded in HPV6 wild type genomes, but deleted during expansion of the HPV6 reference strain (Heinzel et al., 1995) . A similar expansion of this repeat in the HPV18 genome integrated into HeLa-S3 cells could account for the observed sequencing "artifact".
